Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buparlisib plus paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma
NCT04338399Phase 3Completed
- Sponsor
- Adlai Nortye
- Start
- Dec 2020
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of buparlisib in head and neck squamous cell carcinoma (HNSCC), sponsored by Adlai Nortye. Started Dec 2020; status: completed.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04338399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338399.